CeriBell (NASDAQ:CBLL) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

CeriBell (NASDAQ:CBLL) announced its quarterly earnings data on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04), FiscalAI reports. The firm had revenue of $29.34 million during the quarter, compared to the consensus estimate of $29.16 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.

CeriBell Trading Up 4.9%

CBLL stock traded up $1.31 during midday trading on Tuesday, hitting $28.27. The company had a trading volume of 665,677 shares, compared to its average volume of 366,242. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -16.06 and a beta of 0.94. The stock’s 50 day moving average price is $24.98 and its 200 day moving average price is $20.82. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell has a 52 week low of $10.85 and a 52 week high of $28.89.

Insider Activity at CeriBell

In other news, VP David Foehr sold 9,255 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total transaction of $224,433.75. Following the sale, the vice president directly owned 34,144 shares of the company’s stock, valued at $827,992. This represents a 21.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CTO Raymond Woo sold 4,887 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $24.33, for a total value of $118,900.71. Following the transaction, the chief technology officer owned 203,118 shares in the company, valued at $4,941,860.94. This represents a 2.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 174,905 shares of company stock valued at $4,312,995 over the last 90 days. Company insiders own 17.70% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. TD Cowen upped their target price on shares of CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. BTIG Research restated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a report on Friday, September 11th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 price objective on shares of CeriBell in a research report on Thursday, September 3rd. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. Finally, Barclays upgraded shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and an average price target of $27.00.

CeriBell Company Profile

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.